Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 17, Number 3—March 2011

Letter

Mycobacterium mageritense Pulmonary Disease in Patient with Compromised Immune System

R. Gordon HuthComments to Author , Barbara A. Brown-Elliott, and Richard J. Wallace
Author affiliations: Author affiliations: University of Texas Southwestern Residency Programs, Austin, Texas, USA (R.G. Huth); University of Texas Health Science Center, Tyler, Texas, USA (B.A. Brown-Elliott, R.J. Wallace, Jr.)

Main Article

Table

In vitro activity of 23 isolates of Mycobacterium mageritense, United States, 2009*

Antimicrobial agent
 No. isolates tested
 MICs of current isolate, μg/mL
 Intermediate breakpoint, μg/mL
 MIC range, μg/mL
 MIC50, μg/mL
 MIC90, μg/mL
 % S/I
Amikacin 23 8 32 <1–32 16 32 100
Cefoxitin 23 16 32–64 <8–256 32 64 91
Ciprofloxacin 23 0.25 2 <0.25–0.5 0.25 0.5 100
Clarithromycin† 23 8 4 1–>64 >32 >64 4
Doxycycline 22 1 2–8 0.25–>64 8 >32 50
Imipenem 22 4 8 <0.5–8 2 4 100
Linezolid 22 4 16 <2–16 4 8 100
Sulfamethoxazole 21 4 32 <2–32 8 32 100
Trimethoprim/sulfamethoxazole 6 1/19 2/38‡ <0.25/4.8– 2/38 0.5/9.5 2/38 100
Tobramycin 23 <2 8 2–64 >16 >32 30
Tigecycline 5 0.12 –§ <0.03–0.12 0.06 0.12 NA

*Includes 6 isolates previously reported (2). S, susceptible; I, intermediate; NA, not available.
†Three days’ incubation.
‡Proposed breakpoint (7).
§No Clinical and Laboratory Standards Institute breakpoints established for tigecycline.

Main Article

References
  1. Domenech  P, Jimenez  MS, Menendez  MC, Bull  TJ, Samper  S, Manrique  A, Mycobacterium mageritense sp. nov. Int J Syst Bacteriol. 1997;47:535–40. DOIPubMedGoogle Scholar
  2. Wallace  RJ, Brown-Elliott  BA, Hall  L, Roberts  G, Wilson  RW, Mann  LB, Clinical and laboratory features of Mycobacterium mageritense. J Clin Microbiol. 2002;40:2930–5. DOIPubMedGoogle Scholar
  3. Appelgren  P, Farnebo  F, Dotevall  L, Studahl  M, Jönsson  B, Petrini  B. Late-onset posttraumatic skin and soft tissue infections caused by rapid-growing mycobacteria in tsunami survivors. Clin Infect Dis. 2008;47:e11–6. DOIPubMedGoogle Scholar
  4. Gira  AK, Reisenauer  AH, Hammock  L, Nadiminti  U, Macy  JT, Reeves  A, Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol. 2004;42:1813–7. DOIPubMedGoogle Scholar
  5. Miki  M, Shimizukawa  M, Okayama  H, Kazumi  Y. Case of pulmonary Mycobacterium mageritense infection: the difficulty of differential diagnosis of granulomatous lung disease. Kekkaku. 2007;82:189–94.PubMedGoogle Scholar
  6. Steingrube  VA, Gibson  JL, Brown  BA, Zhang  Y, Wilson  RW, Rajagopalan  M, PCR amplification and restriction endonuclease analysis of a 65-kiloDalton heat shock protein gene sequence for taxonomic separation of rapidly growing mycobacteria [ERRATUM 1995;33:1686]. J Clin Microbiol. 1995;33:149–53.PubMedGoogle Scholar
  7. Woods  GL, Brown-Elliott  BA, Desmond  EP, Hall  GS, Heifets  L, Pfyffer  GE, Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes; approved standard. NCCLS Document M24-A. Wayne (PA): Clinical and Laboratory Standards Institute; 2003.
  8. Adékambi  T, Colson  P, Drancourt  M. rpoB-based identification of nonpigmented and late pigmented rapidly growing mycobacteria. J Clin Microbiol. 2003;41:5699–708. DOIPubMedGoogle Scholar
  9. Griffith  DE, Aksamit  T, Brown-Elliott  BA, Catanzaro  A, Daley  C, Gordin  F, An official ATS/IDSA statement: diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367–416. DOIPubMedGoogle Scholar
  10. Nash  KA, Andini  N, Zhang  Y, Brown-Elliott  BA, Wallace  RJ Jr. Intrinsic macrolide resistance in rapidly growing mycobacteria. Antimicrob Agents Chemother. 2006;50:3476–8. DOIPubMedGoogle Scholar

Main Article

Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external